Adamax Spray

The row below carries a price per mg figure: listed price divided by stated peptide content, excluding shipping and codes. It is the same calculation applied on every compound page, so a figure here is directly comparable to one anywhere else on the site.

We currently track a single listing for this compound. When a second vendor is added the rows are ordered by measured $/mg, and the flags for testing and shipping are computed from the data shown. Each row carries its own verification date.

The endotoxin values are not in conflict — they are different reporting limits rather than different measurements. "NMT 0.05" and "< 1.25" both state that nothing was detected above the respective assay threshold. The content figures agree to within about 1.5%.

One display inconsistency: the QC panel header reads "5 passed · 2 reported" while the lot card states "8 assays passed," and the Appearance row present on their other products is absent here — reasonable for a solution rather than a powder, but it makes the count read inconsistently.

"Adamax," "N-Acetyl Semax Adamantane," and "Adamantane Semax" all imply an adamantyl group — a rigid tricyclic C10H15 cage commonly used in medicinal chemistry to raise lipophilicity and metabolic stability.

Every supplier examined that publishes a sequence gives the same one:

That is Semax (Met-Glu-His-Phe-Pro-Gly-Pro) extended at the C-terminus by Ala-Gly and acetylated at the N-terminus. There is no adamantyl group in it. An adamantyl substituent would add roughly 134 Da; an adamantane-1-carbonyl group roughly 162 Da.

It is not a single vendor's error. Conscientia Industrial, a manufacturer, describes the compound in prose as "modified with N-acetyl and adamantane groups to enhance its metabolic stability and lipophilicity" and then lists the sequence as Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly-OH on the same page.

At least one supplier acknowledges the problem One supplier states that Adamax and Adamantane Semax are used interchangeably, that multiple technical references describe an adamantane modification, and advises researchers to compare listed specifications because naming conventions vary between suppliers.

The material sold as Adamax is specified by suppliers as an acetylated nonapeptide. The "adamantane" element of the name is not supported by any published sequence found. Anyone sourcing this compound should verify against the lot mass spectrum rather than the product name.

Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly-OH Ac-MEHFPGPAG

Semax Met-Glu-His-Phe-Pro-Gly-Pro 7 residues Adamax Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly 9 residues, N-acetylated

Two modifications relative to Semax: an N-terminal acetyl cap and a C-terminal Ala-Gly extension. Both are conventional strategies for slowing aminopeptidase and carboxypeptidase cleavage.

Molecular formula and weight — conflicting values Suppliers publishing the same sequence report different formulas.

Only one pair is arithmetically consistent with that sequence.

Working from the sequence: the nine residues sum to 1086.17 Da as free amino acids. Removing eight waters for the eight peptide bonds gives 942.01. Adding the N-terminal acetyl group (+42.04) gives 984.05, and element counts resolve to C44H61N11O13S.

The first pair therefore agrees with the sequence published for this compound.

The alternative figure differs from it by +C6H8 −O2, which does not correspond to acetylation, amidation, adamantylation, or any other standard modification, and cannot be reconciled with the same sequence.

Use C44H61N11O13S / 984.05 for the acetylated nonapeptide, and treat a reported mass near 1032 as describing a different or incorrectly specified material.

This listing is supplied as a ready-to-use solution. Lyophilized powder is the more common format elsewhere:

Appearance (powder) white to off-white lyophilized powder Solubility water; also DMSO Purity spec ≥ 98.0% HPLC typical Water content ≤ 8.0% (manufacturer spec) Acetate content ≤ 15.0% (manufacturer spec) Storage (powder) −20 °C, sealed, protected from light and moisture Shelf life (powder) 24 months

The acetate specification matters for anyone calculating concentration. Up to 15% of a lyophilized mass may be acetate counterion rather than peptide, which is why net peptide content by HPLC is the figure to work from rather than vial fill weight.

The position is therefore:

Semax a genuine literature, including Russian clinical work and mechanistic studies on BDNF/TrkB Adamax no published studies under this name; no CAS number assigned; no independent pharmacology

Every mechanistic statement below is Semax data. None of it has been demonstrated for the nonapeptide. The two modifications that define Adamax — acetylation and C-terminal extension — are exactly the kind of change that can alter potency, receptor interaction and metabolic fate, so extrapolation is an assumption rather than a finding.

Semax is a synthetic heptapeptide derived from ACTH(4-10). It comprises the ACTH(4-7) fragment Met-Glu-His-Phe with a C-terminal Pro-Gly-Pro tripeptide, which confers resistance to enzymatic degradation. Developed in Russia, where it has regulatory approval for certain neurological indications.

The central mechanistic finding. Semax has been reported to regulate BDNF and TrkB expression in rat hippocampus, positioning the compound as acting on neurotrophic signalling rather than as a classical receptor agonist.

(Dolotov et al., Brain Research, 2006)

Comparative work on the temporal dynamics of NGF and BDNF gene expression across rat hippocampus, frontal cortex and retina under Semax.

(Shadrina et al., Journal of Molecular Neuroscience, 2010)

In rat focal cerebral ischemia, Semax affected expression of genes related to immune and vascular systems — a transcriptome-level rather than single-target account.

(Medvedeva et al., BMC Genomics, 2014)

Russian clinical literature reports efficacy at different stages of ischemic stroke. Published in Russian-language neurology journals and not independently replicated outside that literature.

(Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018)

A review of protective properties of ACTH(4-7)PGP at the molecular level.

(International Journal of Molecular Sciences, 2020)

The Alzheimer's Drug Discovery Foundation maintains a Cognitive Vitality review of Semax, useful as a non-vendor appraisal of the strength of the evidence.

Adamax is not an approved drug in any jurisdiction. It has no assigned CAS number and no dedicated clinical or preclinical literature under this name.

Semax, the parent compound, holds regulatory approval in Russia for certain neurological indications. It is not FDA-approved, and approval of a parent compound in one jurisdiction confers nothing on an analogue.

Material supplied for laboratory use is a research chemical. It is not a drug, food, cosmetic, or dietary supplement, has not been evaluated by the FDA, and is not intended for human or veterinary use.